145 related articles for article (PubMed ID: 34559198)
1. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
Angenendt L; Wöste M; Mikesch JH; Arteaga MF; Angenendt A; Sandmann S; Berdel WE; Lenz G; Dugas M; Meshinchi S; Schliemann C; Rössig C
Blood Adv; 2021 Nov; 5(21):4413-4421. PubMed ID: 34559198
[TBL] [Abstract][Full Text] [Related]
2. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Angenendt L; Bormann E; Pabst C; Alla V; Görlich D; Braun L; Dohlich K; Schwöppe C; Bohlander SK; Arteaga MF; Wethmar K; Hartmann W; Angenendt A; Kessler T; Mesters RM; Stelljes M; Rothenberg-Thurley M; Spiekermann K; Hébert J; Sauvageau G; Valk PJM; Löwenberg B; Serve H; Müller-Tidow C; Lenz G; Wörmann BJ; Sauerland MC; Hiddemann W; Berdel WE; Krug U; Metzeler KH; Mikesch JH; Herold T; Schliemann C
Leukemia; 2019 Dec; 33(12):2830-2841. PubMed ID: 31182782
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of CALCRL-associated prognostic genes in acute myeloid leukemia.
Huang Z; Zhang H; Xing C; Zhang L; Zhu H; Deng Z; Yin L; Dong E; Wang C; Peng H
Gene; 2022 Jan; 809():146009. PubMed ID: 34655717
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
5. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
[TBL] [Abstract][Full Text] [Related]
6. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
Grandits AM; Wieser R
Exp Hematol; 2021 Jul; 99():1-11. PubMed ID: 34029637
[TBL] [Abstract][Full Text] [Related]
8. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
[TBL] [Abstract][Full Text] [Related]
9.
Wang R; Li M; Bai Y; Jiao Y; Qi X
J Oncol; 2022; 2022():3024360. PubMed ID: 35342399
[TBL] [Abstract][Full Text] [Related]
10. Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
Sha K; Lu Y; Zhang P; Pei R; Shi X; Fan Z; Chen L
Clin Transl Oncol; 2021 Mar; 23(3):648-656. PubMed ID: 32776271
[TBL] [Abstract][Full Text] [Related]
11. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pretreatment telomere length as a prognostic marker in intermediate-risk acute myeloid leukemia.
Gu R; Cao J; Wei S; Gong X; Wang Y; Mi Y; Zhang J; Qiu S; Rao Q; Wang M; Wei H; Wang J
Int J Lab Hematol; 2021 Dec; 43(6):1510-1515. PubMed ID: 34288423
[TBL] [Abstract][Full Text] [Related]
13. Methylation pattern of calcitonin (CALCA) gene in pediatric acute leukemia.
Ismail EA; El-Mogy MI; Mohamed DS; El-Farrash RA
J Pediatr Hematol Oncol; 2011 Oct; 33(7):534-42. PubMed ID: 21423046
[TBL] [Abstract][Full Text] [Related]
14. The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia.
Niavarani A; Horswell S; Sadri R; Bonnet D
Ann Hematol; 2016 Jan; 95(2):179-90. PubMed ID: 26499507
[TBL] [Abstract][Full Text] [Related]
15. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
16. Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.
Lin X; Wang Z; Wang Y; Feng W
Int J Clin Exp Pathol; 2015; 8(11):14658-66. PubMed ID: 26823789
[TBL] [Abstract][Full Text] [Related]
17. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
Canaani J; Labopin M; Socié G; Nihtinen A; Huynh A; Cornelissen J; Deconinck E; Gedde-Dahl T; Forcade E; Chevallier P; Bourhis JH; Blaise D; Mohty M; Nagler A
Am J Hematol; 2017 Jul; 92(7):653-659. PubMed ID: 28370339
[TBL] [Abstract][Full Text] [Related]
18. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
19.
Bai H; Zhou M; Zeng M; Han L
DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin receptor family evolution and fishing for function using in silico promoter analysis.
Martins R; Vieira FA; Power DM
Gen Comp Endocrinol; 2014 Dec; 209():61-73. PubMed ID: 24815885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
